The content of this website has been produced in line with the BOSULIF® (bosutinib) Summary of Product Characteristics for Great Britain and Northern Ireland. For BOSULIF® (bosutinib) Prescribing Information Click here. Adverse event reporting information can be found at the bottom of the page.
*MMR (≤0.1% BCR-ABL1 transcripts on the international scale in patients with ≥3000 ABL transcripts assessed at month 3).
†Adjusted for Sokal risk group and region at time of random assignment.
‡MR4, ≤0.01% BCR-ABL1 transcripts on the international scale.
§MR4.5, ≤0.0032% BCR-ABL1 transcripts on the international scale.
ABL, Abelson; BCR, breakpoint cluster region; CI, confidence interval; CML, chronic myelogenous leukaemia; mITT, modified intention-to-treat; MMR, major molecular response; MR, molecular response; OR, odds ratio.
*Patients who received one or more doses of study drug
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CML, chronic myelogenous leukaemia; SmPC, Summary of Product Characteristics.
Adapted from: Brümmendorf TH, et al. Leukemia 2022. doi: 10.1038/s41375-022-01589-y Supplementary materials.
References:
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024